JeanMarie Guenot is a business executive in the pharmaceutical and biotechnology industry with over 20 years of experience. She also has a working experience with all stages of companies both private and public in pharmaceutical R&D, business development, commercial and corporate development, venture capital, and project alliance management. She has worked in various fields in therapeutics and has a high level of experience in rebuilding and building of companies.
Jeanmarie Guenot holds the post of the president and the CEO of the Aphivena Therapeutics, Inc., which develops innovative bifunctional antibody therapies recommended for hematologic malignancies. The company is located in San Francisco.
Jeanmarie Guenot did build and run SKS Ocular, which is an incubator for the ophthalmic company. She was a business advisor of Hoffmann-la Roche based in Shanghai. She is also the vice president of corporate and business development, where she has lead mergers and acquisitions, licensing and alliance management for portfolios of commercial products and R&D of PDL.
JeanMarie Guenot has negotiated and led the 50:50 co-development of Biogenic Idec-PDL, and also the strategic collaboration of commercialization in which the candidates of autoimmune disease drug and three phase two cancer were involved. She is also the licenser of the oncology’s ophthalmic indication to the ophthoteh. She has experience in alliance management, portfolio, and project management in oncology sectors on guenotllc.com.
JeanMarie’s career journey started at Atlas Venture, where she built companies of life science and managed the capital investments of the project. Her scientific career journey began at Hoffmann-la Roche where she was the principal scientist of pre-clinical R&D. She developed and discovered drugs for inflammation, metabolic diseases, oncology and autoimmune.
She trained in medicinal and physical chemistry focusing on protein structure prediction, NRM and X-ray refinement, semi-empirical and quantum mechanical methods, molecular dynamics, and drug design according to amphivena.com. She acquired her degree from the University of California located in San Francisco and her MBA at the University of Pennsylvania in the Wharton school.